next-generation modalities are driving new antibody discovery, with several companies, including harbour biomed and nona biosciences, involved in this area of research. the use of emerging modalities and technologies, such as ai-powered platforms, is expected to advance biotherapeutic innovation and potentially lead to new treatments, including those for obesity. the field appears to be experiencing growth and development, with companies evolving their brands and appointing new leadership to support their efforts.